Type your tag names separated by a space and hit enter

luliconazole

General

Pronunciation:
loo-li-kon-a-zole


Trade Name(s)

  • Luzu

Ther. Class.
antifungals

Pharm. Class.
azoles

Indications

Topical treatment of interdigital tinea pedis, tinea cruris and tinea corporis.

Action

  • Inhibits an enzyme necessary for ergosterol synthesis, required for fungal cell membranes.
  • Antifungal action .

Therapeutic Effect(s):

Resolution of dermal fungal infection.

Spectrum:

Active against Trichyphyton rubrum and Epidermpophyton floccosum.

Pharmacokinetics

Absorption: Small amounts are systemically absorbed.

Distribution: Unknown.

Protein Binding: >99%

Metabolism and Excretion: Unknown.

Half-life: Unknown.

TIME/ACTION PROFILE (improvement/resolution of infection)

ROUTEONSETPEAKDURATION
topicalunknown3–4 wk†unknown
†Following initiation of treatment.

Contraindication/Precautions

Contraindicated in:

  • None noted.

Use Cautiously in:

  • OB: Lactation:Safety not established;
  • Pedi: Safety and effectiveness not established.

Adverse Reactions/Side Effects

Derm: application site reactions

* CAPITALS indicate life-threatening.
Underline indicate most frequent.

Interactions

Drug-Drug

May inhibit the activity of the CYP2C19 enzymes.

Route/Dosage

Topical: (Adults) Interdigital tinea pedis Apply to affected and surrounding areas once daily for two weeks; Tinea cruris and tinea corporis Apply to affected and surrounding areas once daily for one week.

Availability

Cream: 1%

Assessment

  • Inspect involved areas of skin and mucous membranes before and frequently during therapy. Increased skin irritation may indicate need to discontinue medication.

Potential Diagnoses

Implementation

  • Consult health care professional for proper cleansing technique before applying medication.
  • Topical: For Interdigital tinea pedis: Apply thin layer to cover affected area and approximately 1 inch of immediate surrounding area completely daily for 2 wk.
    • For Tinea Cruris or Tinea Corporis: Apply thin layer to affected area and approximately 1 inch of immediate surrounding area daily for 1 wk.
    • Avoid the use of occlusive wrappings or dressings unless directed by health care professional. Wash hands after application.

Patient/Family Teaching

  • Instruct patient to apply medication as directed for full course of therapy, even if feeling better. Emphasize the importance of avoiding the eyes and vagina.
  • Patients with athlete's foot should be taught to wear well-fitting, ventilated shoes, to wash affected areas thoroughly, and to change shoes and socks at least once a day.
  • Advise patient to report increased skin irritation or lack of response to therapy to health care professional.
  • Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and consult health care professional before taking any new medications.
  • Advise female patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

Evaluation/Desired Outcomes

Decrease in skin irritation and resolution of infection.

luliconazole is a sample topic from the Davis's Drug Guide.

To view other topics, please or purchase a subscription.

Medicine Central™ is a quick-consult mobile and web resource that includes diagnosis, treatment, medications, and follow-up information on over 700 diseases and disorders, providing fast answers—anytime, anywhere. Learn more.

Citation

Quiring, Courtney, et al. "Luliconazole." Davis's Drug Guide, 16th ed., F.A. Davis Company, 2019. Medicine Central, im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/110104/all/luliconazole.
Quiring C, Sanoski CA, Vallerand AH. Luliconazole. Davis's Drug Guide. 16th ed. F.A. Davis Company; 2019. https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/110104/all/luliconazole. Accessed April 19, 2019.
Quiring, C., Sanoski, C. A., & Vallerand, A. H. (2019). Luliconazole. In Davis's Drug Guide. Available from https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/110104/all/luliconazole
Quiring C, Sanoski CA, Vallerand AH. Luliconazole [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2019. [cited 2019 April 19]. Available from: https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/110104/all/luliconazole.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - luliconazole ID - 110104 A1 - Quiring,Courtney, AU - Sanoski,Cynthia A, AU - Vallerand,April Hazard, BT - Davis's Drug Guide UR - https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/110104/all/luliconazole PB - F.A. Davis Company ET - 16 DB - Medicine Central DP - Unbound Medicine ER -